An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.

Trial Profile

An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Giant cell arteritis
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 28 Jul 2017 Planned initiation date changed from 7 Jul 2017 to 2 Aug 2017.
    • 30 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top